MEF2D and hepatocellular carcinoma: Wang et al. reported that KDM1A interacts with MEF2D to increase PD-L1 expression in HCC cells, and miR-329-3p targeting of KDM1A inhibits tumor-induced immunosuppression and sensitizes HCC cells to T cell-mediated cytotoxicity, by modulating PD-L1 expression [294].